INTRODUCTION
============

Protein deacetylases counter the action of protein acetyl transferases ([@b120-molce-39-2-87]) by removing acetyl groups added to lysine residues by the latter. This large family of enzymes is often referred to as histone deacetylases (HDACs), but histones are certainly not their only substrates. In mammals, HDACs are broadly divided into four classes (I--IV) ([@b123-molce-39-2-87]). Class I HDACs (HDACs 1, 2, 3 and 8) are homologous with the yeast *Reduced Potassium Deficiency 3* (*RPD3*), are ubiquitously expressed, and are primarily localized to the nucleus. Class II HDACs (namely HDACs 4, 5, 6, 7, 9 and 10), which are homologues of yeast *Histone DeAcetylase 1* (*HDA1*), shuttle between the nucleus and the cytoplasm, and are more tissue specific in terms of expression. HDAC11 has only fairly low homology to both *RPD3* and *HDA1*, and has been proposed to constitute a separate class IV ([@b35-molce-39-2-87]) so as to be distinguishable from the class III HDACs, or sirtuins.

Sirtuins are a family of proteins with homologies to the *Silence Information Regulator 2* (*SIR2*) gene of the yeast *S. cerevisiae* ([@b10-molce-39-2-87]), and are not structurally homologous to the other HDACs. Lysine deacetylation by sirtuins is coupled to the cleavage of a key intermediate of cellular energy metabolism, nicotinamide adenine dinucleotide (NAD^+^), into nicotinamide and 1′-O-acetyl-ADP-ribose ([@b111-molce-39-2-87]) or 2′- and 3′-O-acetyl-ADP-ribose ([@b53-molce-39-2-87]). The activities of sirtuins are thus obligatorily dependent on cellular NAD^+^, inhibited by the reaction product nicotinamide, and effectively influenced by cellular metabolic and redox states. Homologues of yeast *SIR2* exist in lower model organisms, such as the nematode *C. elegans sir-2.1* and the fruit fly *D. melanogaster Sir2*. The mammalian genome has seven sirtuin paralogues (Sirt1-7), with Sirt1 having the highest homology to yeast *Sir2* ([@b40-molce-39-2-87]; [@b41-molce-39-2-87]). In yeast, Sir2p regulates chromatin silencing, and reduces the accumulation of rDNA circles during yeast replicative aging ([@b104-molce-39-2-87]). *SIR2* and its metazoan orthologues have been prominently associated with lifespan extension ([@b51-molce-39-2-87]; [@b113-molce-39-2-87]), in particular that induced by caloric or dietary restriction (CR/DR) ([@b98-molce-39-2-87]; [@b122-molce-39-2-87]). A large number of studies have connected Sirt1 expression and/or activation by compounds such as resveratrol, with increase health span and lifespan ([@b36-molce-39-2-87]). However, the notion that Sirt1 is a mediator of CR effects and a longevity factor in mammals and humans has been controversial in two major ways. There were doubts about the specificity and effectiveness of natural and synthetic Sirt1 activators such as resveratrol and SRT1720 ([@b58-molce-39-2-87]; [@b89-molce-39-2-87]). Sirt1, at least in certain contexts ([@b71-molce-39-2-87]; [@b109-molce-39-2-87]), may also promote aging. Sirt1's role in longevity has been more extensively investigated in yeast and lower invertebrate models, and although the notion of Sirt1 as a longevity gene has a great deal of support, there were also controversies and evidence to the contrary ([@b12-molce-39-2-87]). The demonstration of Sirt1's role in lifespan extension in mammalian models proved difficult. Sirt1's knockout phenotype was difficult to interpret, as the mice often died early due largely to developmental defects ([@b18-molce-39-2-87]; [@b73-molce-39-2-87]). Earlier work on transgenic over-expression of Sirt1 in mice did not result in a significant increase in lifespan ([@b47-molce-39-2-87]). More recent findings have, however, provided some reconciliation of the contrasting results and opinions. The mode of action of sirtuin-activating compounds (STACs), possibly via an allosteric mechanism, has been better clarified ([@b52-molce-39-2-87]). Additionally, both the transgenic expression of Sirt1 ([@b102-molce-39-2-87]) and the specific activator SRT1720 ([@b77-molce-39-2-87]) have eventually been shown to increase lifespan in mice.

Indeed, dissection of Sirt1's role in CR and aging is difficult because Sirt1 has multiple physiological functions as well as wide-ranging roles in pathological settings. This is due to its astonishingly large repertoire of targets, many of which are key transcription factors associated with important aspects of cell survival and metabolism. Prominent amongst these are the tumor suppressor TP53 ([@b118-molce-39-2-87]), the Forkhead bOX class O (FoxO) family members ([@b11-molce-39-2-87]), and nuclear factor κB (NF-κB) ([@b124-molce-39-2-87]), all key regulators of cell death and survival. Sirt1 represses a key metabolic regulator, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) ([@b93-molce-39-2-87]; [@b106-molce-39-2-87]), via deacetylation of PPARγ coactivator-1α (PGC-1α) ([@b32-molce-39-2-87]; [@b65-molce-39-2-87]; [@b82-molce-39-2-87]; [@b97-molce-39-2-87]), which regulates energy metabolism in skeletal muscle, adipose tissues and the liver. Sirt1 has also been implicated in cellular metabolism through its activation of AMP-dependent kinase (AMPK) via liver kinase B1 (LKB1) ([@b50-molce-39-2-87]; [@b66-molce-39-2-87]; [@b130-molce-39-2-87]), as well as suppression of the mammalian target of rapamycin (mTOR) pathway ([@b33-molce-39-2-87]; [@b49-molce-39-2-87]; [@b70-molce-39-2-87]).

Of the seven mammalian sirtuins, three (Sirt3, Sirt4 and Sirt5) have a primary mitochondrial localization ([@b75-molce-39-2-87]). Sirt1, on the other hand, is primarily nuclear, but its activities have large bearings on mitochondrial biogenesis and turnover. In the ensuing paragraphs, we shall discuss how Sirt1 is functionally associated with the mitochondria. We first look at some evidence for the predominantly nuclear Sirt1 being physically localized at the mitochondria.

SIRT1'S MITOCHONDRIAL LOCALIZATION
==================================

Sirt1 is primarily found in the nucleus of most cell types ([@b75-molce-39-2-87]), and it is not just a *bona fide* histone deacetylase ([@b116-molce-39-2-87]) but also deacetylates histone modifying enzymes such as the histone methyl-transferase SUV39H1 ([@b117-molce-39-2-87]). Both Sirt1 and SUV39H1 are required for the epigenetic control of the rDNA locus for rRNA synthesis ([@b81-molce-39-2-87]), and Sirt1 may also be nucleolar in localization. Befitting its nuclear localization, a majority of Sirt1's known function is associated with deacetylation of transcription factors, as mentioned in the section above. As per all nuclear proteins, it is synthesized in the cytoplasm and imported into the nucleus. Sirt1, however, appears to possess both nuclear localization signals and nuclear export signals, and could shuttle between the cytoplasm and the nucleus ([@b112-molce-39-2-87]). Sirt1's cytoplasmic appearance has been associated with enhanced apoptotic cell death ([@b57-molce-39-2-87]), and also shown to be due to an increased protein stability via oncogenic signaling through the insulin-like growth factor-1-phosphoinositide 3-kinase (IGF-1/PI3 kinase) axis in cancer cells ([@b13-molce-39-2-87]). On the other hand, Sirt1 does have cytosolic substrates whose deacetylation by Sirt1 results in distinct physiological or functional consequences. For instance, the cytoplasmic acetyl-CoA synthetase ([@b42-molce-39-2-87]) and the actin binding protein cortactin ([@b126-molce-39-2-87]) are both deacetylated by Sirt1, and these influence cytosolic fatty acid synthesis and cytoskeletal changes during cell migration, respectively.

Sirt1 and its substrate, PGC-1α, regulate aspects of energy metabolism through the mitochondria, but this was initially thought to occur through their influence on nuclear localized transcription. A rather interesting aspect of Sirt1's activity and function that is less well defined is its extranuclear localization, particularly at the mitochondria ([@b5-molce-39-2-87]). This was first shown by Aquilano and colleagues using both confocal imaging and subcellular fractionation analysis ([@b4-molce-39-2-87]). Both Sirt1 and the nuclear transcription factor PGC-1α could be found in the mitochondria of human cell lines and platelets, as well as in various mouse organs. Within the mitochondria, both deacetylase and its substrate are associated with the mitochondrial DNA (mtDNA) nucleoids ([@b9-molce-39-2-87]), as well as with the mitochondrial transcription factor A (TFAM), a key mitochondrial gene transcription factor and regulator of mtDNA copy number ([@b14-molce-39-2-87]). These findings are fascinating, as they suggest that Sirt1 and PGC-1α may also directly affect mitochondrial transcription. However, the degree of mitochondrial Sirt1 and PGC-1α's functionality in this regard is still uncertain. In the sections that follow, we shall outline findings that point to how Sirt1 mediates aspects of mitochondrial biogenesis and turnover, as well as the controversies associated with these findings.

SIRT1'S DEACETYLATION OF PGC - 1α - METABOLIC REGULATION AND MITOCHONDRIAL BIOGENESIS
=====================================================================================

Mitochondria are dynamic organelles, and inheritance occurs by partitioning existing mitochondria between daughter cells in dividing cells ([@b76-molce-39-2-87]). However, within all cells, either dividing or terminally differentiated, the mitochondria population is constantly renewed, and the steady state number of this organelle represents an equilibrium between mitochondrial biogenesis and eventual degradation through the process of mitophagy ([@b105-molce-39-2-87]; [@b119-molce-39-2-87]). Mitochondrial biogenesis involves the transcription of both nuclear and mtDNA-encoded genes. Mitochondrial biogenesis is orchestrated by the Peroxisome proliferator-activated receptor Gamma Coactivator-1 (PGC-1) family of transcriptional coactivators ([@b6-molce-39-2-87]). The PGC-1 family consists of three members, namely, PGC-1α, PGC-1β and the PGC related coactivator (PRC). PGC-1α, in particular, is often cited as a master regulator of this process. PGC-1α co-activates the transcription of Nuclear Respiratory Factor (NRF) 1 and 2, which, in turn, regulate the transcription of TFAM. TFAM translocates to mitochondrial matrix where it stimulates mitochondrial DNA replication and mitochondrial gene expression.

PGC-1α undergoes several modes of post-translational modification, which includes acetylation and phosphorylation. Acetylation of PGC-1α occurs at several of its lysine residues and is catalyzed by the ubiquitous histone acetyl transferase General control of amino acid synthesis 5 (GCN5) ([@b23-molce-39-2-87]). Acetylation alters PGC-1α's localization within the nucleus, and inhibits its transcriptional activity. Conversely, deacetylation of PGC-1α was shown by several studies to be dependent on Sirt1 activity ([@b2-molce-39-2-87]; [@b23-molce-39-2-87]; [@b32-molce-39-2-87]; [@b37-molce-39-2-87]; [@b65-molce-39-2-87]; [@b82-molce-39-2-87]; [@b86-molce-39-2-87]; [@b97-molce-39-2-87]), which increases PGC-1α's transcriptional activity. PGC-1α is phosphorylated by both Mitogen-activated protein kinase p38 ([@b8-molce-39-2-87]), and the AMP-dependent kinase (AMPK) in skeletal muscle ([@b67-molce-39-2-87]), which also stabilizes the protein and increases its activity. On the other hand, phosphorylation of PGC-1α by AKT/protein kinase B (PKB), downstream of insulin signaling in the liver, is known to decrease its stability and transcriptional activity ([@b68-molce-39-2-87]).

Given the importance of its acetylation status to PGC-1α activity, the connection between Sirt1 and PGC-1α has been a focus of investigations into metabolic regulation and mitochondrial biogenesis. Finkel's group has provided clear biochemical evidence that Sirt1 physically and functionally interacts with PGC-1α ([@b82-molce-39-2-87]), and this interaction could be distinguished by a single amino acid mutation in the putative ADP-ribosyltransferase domain of Sirt1. This mutation abolishes Sirt1's interaction with PGC-1α, but not with two other major substrates, p53 and Foxo3a. In what contexts would this interaction occur? A rather simplified view in this regard is that Sirt1 acts a metabolic and redox sensor of changes in nutrient and energy status, such as those occurring during CR ([@b15-molce-39-2-87]). CR has been shown to significantly increase mitochondrial biogenesis in multiple tissues in mice ([@b85-molce-39-2-87]) and in human muscles ([@b19-molce-39-2-87]). Early work from Puigserver's group showed that Sirt1 is induced during fasting, and induced Sirt1 interacts with PGC-1α to increase the expression of hepatic gluconeogenic genes ([@b97-molce-39-2-87]). The group also showed that fasting induced PGC-1α deacetylation by Sirt1 in skeletal muscle, which is required for the activation of mitochondrial fatty acid oxidation genes ([@b32-molce-39-2-87]). Auwerx's group, on the other hand, showed that resveratrol treatment of mice increased running time and oxygen consumption by the skeletal muscles, which is accompanied by the induction of genes for oxidative phosphorylation and mitochondrial biogenesis ([@b65-molce-39-2-87]). The authors attributed these changes to activation of Sirt1, and a consequential decrease in PGC-1α acetylation and activity. The authors also showed that resveratrol treatment protected mice against diet-induced-obesity and insulin resistance. A more specific Sirt1 activator, SRT1720, likewise enhanced muscle endurance and protected mice from diet-induced obesity and insulin resistance by enhancing oxidative metabolism in skeletal muscle, liver, and brown adipose tissue ([@b29-molce-39-2-87]). Auwerx and colleagues also found that deletion of the poly(ADP-ribose) polymerase-1(PARP-1), a major NAD^+^-consuming enzyme, resulted in increased Sirt1 activity. PARP-1 knockout mice have a higher mitochondrial content, an increase in energy expenditure, and were protected against metabolic disease ([@b7-molce-39-2-87]). The work of Anderson and colleagues ([@b3-molce-39-2-87]) provided dynamical insights as to how Sirt1 may regulate PGC-1α action. The latter's nuclear transcription activity is enhanced by Sirt1-dependent nuclear accumulation and is counter regulated by glycogen synthase kinase beta (GSK3β), which targets PGC-1α for intranuclear proteasomal degradation.

Despite the apparently convincing functional connection between Sirt1 and PGC-1α, whether Sirt1 is critically or directly involved in mitochondrial biogenesis has been controversial. Gurd and colleagues ([@b38-molce-39-2-87]) examined the relationship between Sirt1 levels and activity, PGC-1α and markers of mitochondrial density (such as Cytochrome c Oxidase subunit IV, COXIV) in skeletal and heart muscles, and surprisingly found a largely negative correlation between Sirt1 levels and the rest of the parameters. In fact, overexpression of Sirt1 in muscle downregulated PGC-1α and mtTFA levels, and while muscle stimulation and the AMPK activator AICAR upregulated PGC-1α and COX IV, Sirt1 level was downregulated. The group further showed that while nuclear Sirt1 activity correlated with indices of mitochondrial density, nuclear Sirt1 protein levels were negatively correlated in skeletal and heart muscles ([@b37-molce-39-2-87]). While training did not alter muscle or nuclear Sirt1 protein content in human muscle, it did increase muscle and nuclear PGC-1α and Sirt1 activity. Thus, it is an increased nuclear Sirt1 activity that may actually contribute to exercise-stimulated mitochondrial biogenesis in muscle.

From a more fundamental perspective, Hancock and colleagues ([@b44-molce-39-2-87]) have reexamined the claim that CR resulted in dramatic increases in mitochondrial biogenesis in multiple mouse tissues ([@b85-molce-39-2-87]). In contrast to previous work, the authors found no elevation in PGC-1α levels after CR, and no evidence of any significant elevation in mitochondrial biogenesis markers in heart, brain, skeletal muscle, liver and adipose tissues. Although the authors did not report any measurement of Sirt1 level/activity status or PGC-1α's acetylation status, the study does challenge the reproducibility of the CR-induced mitochondrial phenomenon. Another study directly questioned the role of Sirt1 in exercise-induced mitochondrial biogenesis through PGC-1α decetylation ([@b92-molce-39-2-87]). The authors generated muscle-specific Sirt1 knockout mice (Sirt1 exon 4 was 'floxed' and crossed with Cre driven by muscle creatine kinase promoter), and found that skeletal muscle endurance, mitochondrial oxidative metabolism, and mitochondrial biogenesis were all not impaired. Moreover, mice deficient in muscle Sirt1 are similar to wild-type mice with regard to PGC-1α expression, nuclear translocation, activity, and deacetylation status. The authors further suggest that it is really the changes in GCN5 acetyltransferase activity that are important in regulating PGC-1α activity after exercise, and Sirt1 may not be relevant. Another recent study added to the controversy by showing that resveratrol feeding had no effect on mitochondrial proteins in muscle ([@b48-molce-39-2-87]), while high levels of resveratrol activated AMPK in C2C12 myotubes in culture, which did increase mitochondrial protein levels. The group further showed that Sirt1 silencing or a dominant negative mutant did increase PGC-1α acetylation, and over-expression of Sirt1 reduced it. However, the latter actually suppressing, instead of enhanced PGC-1α's co-activator activity, with a consequential reduction in mitochondrial proteins.

THE CONNECTION BETWEEN SIRT1, AMPK AND PGC-1α IN REGULATING MITOCHONDRIAL FUNCTION
==================================================================================

The discussion above highlights a particularly controversial point pertaining to the effect of resveratrol on PGC-1α and mitochondrial biogenesis, as well as the mode of involvement of the key cellular nutrient and energy status sensor AMPK ([@b45-molce-39-2-87]). Using an inducible knockout model, Sinclair's group has shown that intact Sirt1 in mice is required for resveratrol's activity on mitochondrial biogenesis and function ([@b94-molce-39-2-87]). The authors also showed that with moderate levels of resveratrol, AMPK activation in the system was Sirt1-dependent. Although higher levels of resveratrol could activate AMPK in a Sirt1-independent manner, improvement in mitochondrial function in both cases of moderate and high dosages of resveratrol was not observed in the absence of Sirt1. That Sirt1 may act upstream of AMPK has support in a previous report, which showed that Sirt1 could potentially deacetylate and activate the major AMPK activating kinase, Serine/threonine kinase 11 (STK11) (or liver kinase B1, LKB1) ([@b66-molce-39-2-87]).

Resveratrol's pharmacological effect is multifaceted, and amongst its known effects is the direct activation of AMPK ([@b21-molce-39-2-87]) and inhibition of cAMP-degrading phosphodiesterases ([@b91-molce-39-2-87]). The work of Dasgupta and Milbrandt indicates that resveratrol could directly activate AMPK, at least in certain cell types, in a manner that is completely independent of Sirt1 activity ([@b21-molce-39-2-87]). Another report has also shown that AMPK deficient mice are fairly resistant to the metabolic improvement effect of resveratrol ([@b115-molce-39-2-87]). A role for AMPK in mitochondrial biogenesis in skeletal muscle and other tissues has been extensively documented ([@b31-molce-39-2-87]; [@b63-molce-39-2-87]; [@b95-molce-39-2-87]; [@b96-molce-39-2-87]; [@b129-molce-39-2-87]). In skeletal muscle, AMPK has been shown to directly phosphorylate PGC-1α ([@b55-molce-39-2-87]), and the phosphorylation of Thr-177 and Ser-538 is required for the PGC-1α-dependent induction of its own promoter. It was also demonstrated that a single administration of the AMPK activator AICAR increased the mRNA expression of all PGC-1α isoforms ([@b108-molce-39-2-87]). It is therefore clear that any compound or physiological regimes that elevate AMPK levels may also influence PGC-1α levels/activity and consequent mitochondrial biogenesis, in a manner that may be largely independent of Sirt1.

While some results, such as those of [@b94-molce-39-2-87] are in support of Sirt1 acting upstream of AMPK, others have demonstrated just the opposite. Auwerx's group has shown that AMPK could at least exert an influence on Sirt1 activity by increasing cellular NAD^+^ levels ([@b15-molce-39-2-87]; [@b17-molce-39-2-87]). The work of [@b91-molce-39-2-87] indicated that resveratrol inhibits cAMP phosphodiesterases, thus leading to elevated cAMP levels and the activation of AMPK and cAMP-inducible factors such as the Rap Exchange factor directly activated by cAMP 1 (Epac1). The authors showed that Epac1 is required for resveratrol-mediated increases in NAD^+^ levels, which were abolished by silencing of Epac1. What could be discerned from these remarkably different reports is that the connection between Sirt1, AMPK and PGC-1α is nonlinear, is definitely cell/tissue-type dependent and is influenced by energy and nutrient status.

SIRT1 AND MITOPHAGY
===================

Given Sirt1's role in mitochondrial biogenesis discussed above, it might appear paradoxical that Sirt1 has also been recently implicated in the opposite process, namely, the destruction of damaged or aged mitochondria via mitophagy ([@b125-molce-39-2-87]). A detailed examination of mitophagy and its mechanism is beyond the scope of this review, and the reader is referred to several excellent recent review articles on this topic (Durcan and Fon, 2015; [@b27-molce-39-2-87]; Hamacher-Brady and Brady, 2015; [@b125-molce-39-2-87]). Mitophagy is critically dependent on two factors - the PTEN-induced putative kinase 1 (PINK1) and the E3 ubiquitin ligase Parkin. These proteins act in sensing the functional and health statuses of mitochondria, and mark damaged mitochondria for autophagic disposal ([@b27-molce-39-2-87]). Sirt1's regulation of general macroautophagy is well known ([@b83-molce-39-2-87]) and is broadly viewed as a cellular protective mechanism against stress and death insults ([@b87-molce-39-2-87]; [@b107-molce-39-2-87]). A connection between Sirt1 and mitophagy was first shown by Hwang's group, when the authors found that nicotinamide treatment of primary human fibroblasts extended their replicative lifespan apparently by accelerating autophagic degradation of mitochondria ([@b59-molce-39-2-87]). Nicotinamide decreased mitochondrial mass and increased mitochondrial membrane potential, with elevations of the autophagosome marker light chain 3 (LC3)-II and levels of proteins that regulate mitochondrial fusion and fission.

Nicotinamide can be converted to NAD^+^ by the salvage pathway of NAD^+^ synthesis. A subsequent paper from the Hwang lab indeed suggested that the mitophagic effect of nicotinamide is mediated through an increase of the NAD^+^/NADH ratio and Sirt1 activation ([@b56-molce-39-2-87]), and the mitochondrial phenotype induced by nicotinamide could be mimicked with the Sirt1 activator SRT1720. Mitochondrial dysfunction in Xeroderma Pigmentosum group A (XPA), a nucleotide excision DNA repair disorder, is characterized by defective mitophagy ([@b28-molce-39-2-87]). This is apparently due to hyperactivation of the DNA damage sensor PARP-1, a major NAD^+^ consuming enzyme, and the consequent lowering of Sirt1 activity. Another recent report indicated that the Sirt1 activator resveratrol acts through a signaling axis that involves Sirt1-Sirt3 and PINK1/Parkin-mediated mitophagy, resulting in cardio-protection (Das et al., 2014). Furthermore, loss of Sirt1 in the luminal epithelium in human prostate cancer delayed Parkin translocation to the mitochondria and reduced mitophagy (Di Sante et al., 2015).

SIRT1, PGC-1α AND NEURODEGENERATIVE DISEASES
============================================

A particularly interesting aspect of the findings discussed above is Sirt1's known role in protection against neurodegenerative disorders ([@b84-molce-39-2-87]; [@b110-molce-39-2-87]; [@b127-molce-39-2-87]). Over the years, Sirt1 activity has been extensively associated with neuroprotection, and autophagy (or more specifically, mitophagy) induction could be part of its protective repertoire. Sirt1 activity is known to attenuate α-synuclein aggregation and toxicity, a hallmark of Parkinson's disease (PD) ([@b1-molce-39-2-87]; [@b24-molce-39-2-87]; [@b101-molce-39-2-87]). The mitophagy regulators PINK1 and Parkin are both encoded by PD susceptibility genes that are mutated in patients with juvenile or early-onset Parkinsonism ([@b80-molce-39-2-87]). Interestingly, a genetic screen in *Drosophila* found that ectopic expression of the fly *Sir2* rescued mitochondrial defects in PINK1-null mutants (but not parkin mutants) ([@b62-molce-39-2-87]).

A better known connection between Sirt1 and neurodegenerative diseases is not a mitophagy factor, but rather PGC-1α ([@b99-molce-39-2-87]; [@b114-molce-39-2-87]). PGC-1α suppression promotes α-synuclein accumulation in cellular models of PD ([@b26-molce-39-2-87]). The Zn-finger protein Parkin-interacting substrate (PARIS, or ZNF746) accumulates in cellular models of Parkin inactivation and in the human PD brain ([@b103-molce-39-2-87]). PARIS represses the expression of PGC-1α and NRF-1, and transgenic overexpression of PARIS leads to the selective loss of dopaminergic neurons in the substantia nigra, the disease-susceptible neuron group in PD. Another report indicated that loss of Parkin in cells from patients with early-onset PD increased PGC-1α, but the elevated PGC-1α appeared transcriptionally non-functional ([@b88-molce-39-2-87]). Meta-analysis of gene expression profiles and molecular pathways clearly implicated PGC-1α-responsive genes amongst those downregulated in PD ([@b128-molce-39-2-87]). Co-transduction of adenovirus carrying human PGC-1α in rat E17 mid-brain neuron cultures attenuated dopaminergic neuron loss induced by either mutant α-synuclein, or the mitochondrial respiratory chain Complex I-inhibitor rotenone. Transgenic mice that over-express PGC-1α in substantia nigra's dopaminergic neurons are resistant to degeneration induced by the neurotoxin MPTP ([@b79-molce-39-2-87]).

Loss of PGC-1α is also a well-known feature in Huntington's disease (HD), a hereditary disorder where aggregation of mutant Huntingtin protein with an extended polyglutamine tract causes striatal neuron loss ([@b100-molce-39-2-87]). Nuclear accumulation of mutant huntingtin repressed PGC-1α gene transcription by associating with its promoter ([@b20-molce-39-2-87]), and over-expression of PGC-1α could partially reverse the toxicity of mutant huntingtin in cultured striatal neurons. Interestingly, nicotinamide could upregulate PGC-1α and the neuroprotective brain-derived neurotrophic factor (BDNF) in a transgenic mouse model of HD, and improve motor deficits ([@b46-molce-39-2-87]). Another study with inducible PGC-1α expression in HD mice not only rescued the HD phenotype and spared neurons, but could result in significant elimination of mutant Huntingtin aggregates ([@b64-molce-39-2-87]). Given PGC-1α's beneficial effect on a multitude of neurodegenerative pathologies, it is likely that the neuroprotective effect of Sirt1 may, at least in part, be exerted through activation of PGC-1α.

While all of the above results appear to attest to the promise of PGC-1α as a drug target in PD and HD, one must avoid generalizing PGC-1α's potential beneficial effects on other neurodegenerative diseases. In particular, a recent report has shown that crossing of an Alzheimer's disease (AD) mouse model (Tg19959 mice) with transgenic strains over-expressing human PGC-1α exacerbated amyloid and tau accumulation ([@b25-molce-39-2-87]).

OTHER SIRT1-REGULATED FACTORS/SUBSTRATES IN MITOCHONDRIAL FUNCTION
==================================================================

Sirt1's protective activity against the detriments of mitochondrial dysfunction involves other Sirt1 substrates, particularly transcription factors that influence mitochondrial activity. One such group of factors are members of the Forkhead box O (FoxO) transcription factor family ([@b121-molce-39-2-87]). Sirt1 is known to deacetylate members of the FoxO family, particularly in response to stress ([@b11-molce-39-2-87]). *Drosophila Sir2* expression prevented the demise of fly dopaminergic neurons in PINK1-null mutants in a dFOXO-dependent manner ([@b62-molce-39-2-87]). Activation of FoxO3a, in particular, has been shown to inhibit mitochondrial gene expression, causing a reduction in mitochondrial DNA copy number and respiratory activity ([@b30-molce-39-2-87]). In fact, a declined in nuclear NAD^+^, and a consequentially diminished Sirt1 activity, was also found to underlie a specific loss of mitochondrial-encoded subunits of the oxidative phosphorylation system ([@b34-molce-39-2-87]).

Interestingly, FoxO3a could translocate into the mitochondria where it could potentially be a substrate of mitochondrial Sirt3 ([@b54-molce-39-2-87]). FoxO3a mitochondrial translocation was also shown to occur during GTP-induced erythroid differentiation ([@b74-molce-39-2-87]). Recent work in *C. elegans* has indicated that worm *sir2.1* mediates longevity via the mitochondrial unfolded protein response (UPR^mt^) and the activation of the worm FoxO orthologue DAF-16 ([@b78-molce-39-2-87]). It was further shown that inhibition of the mitochondrial chaperone TRAP1 generates a FoxO-dependent retrograde cell protective signal from the mitochondria to the nucleus ([@b61-molce-39-2-87]). Sirt1's modulation of FoxO activity could therefore influence mitochondria function via gene expression in the nucleus, as well as affecting retrograde signaling from the mitochondria to the nucleus.

A few other Sirt1-modified transcription factors could also have a role, either directly or indirectly, in mitochondrial activity and function. Sirt1 deacetylates and represses the activity of the hypoxia inducible factor 1-alpha (HIF-1α) ([@b69-molce-39-2-87]). HIF-1α is known to repress mitochondrial function and oxygen consumption by inducing pyruvate dehydrogenase kinase 1 (PDK1) ([@b90-molce-39-2-87]), and Sirt1 activity may thus influence mitochondrial respiratory function via the former. One prominent transcription factor substrate of Sirt1 is the tumor suppressor TP53 ([@b118-molce-39-2-87]), and Sirt1 deacetylation of p53 suppresses its transactivation capacity and promotes cell survival ([@b72-molce-39-2-87]). Interestingly, it has been shown that mouse embryonic stem (mES) cells produces endogenous reactive oxygen species (ROS), which causes p53 translocation into the mitochondria in the presence of Sirt1, but induces p53 nuclear translocation in Sirt1-null mES cells ([@b43-molce-39-2-87]). Sirt1 activity may therefore influence mitochondria-mediated apoptosis by influencing mitochondrial translocation of factors such as p53. Another transcription factor that is deacetylated by Sirt1 which has known roles in mitochondrial physiology is the Nuclear factor erythroid 2-related factor 2 (Nrf2) ([@b60-molce-39-2-87]). Nrf2 and its inhibitor, the Kelch-like ECH associated protein 1 (Keap1), are master regulators of the cellular anti-oxidative response, and have key roles in cellular bioenergetics ([@b22-molce-39-2-87]). It is clear from these examples that Sirt1 activity exerts a complex and multi-effector mediated influence on mitochondrial functions.

CONCLUSION
==========

In this review, I discussed evidence for Sirt1's regulation of mitochondrial biogenesis and turnover, particularly in relation to PGC-1α (see [Fig. 1](#f1-molce-39-2-87){ref-type="fig"}). The emerging view in the field is that Sirt1 activity could exert important influence on mitochondrial function, but the degree of influence is likely cell type- and physiological context-dependent. Sirt1 activation could promote mitochondrial biogenesis in conditions of energy deficiency associated with disease and injury. On the other hand, it could also have an important role in triggering the demise or turnover of damaged mitochondria. It is conceivable that both pathways would occur in parallel. Should one pathway occur preferentially over the other, which pathway will predominate would likely depend on the nature of disease/injury, the relevant Sirt1 substrates available, and the cell's energetic and metabolic status, such as the availability of NAD^+^. For example, factors that result in direct mitochondrial damage may induce a higher rate of mitophagy. In terminally differentiated cells with acute energy requirements such as neurons, sustaining a steady supply of mitochondria and salvaging whatever that remains functional could be important to ensure survival. In dividing cells, a quick mitophagic clearance of damaged mitochondria may be more urgent so that these are not passed down to daughter cells during division. On the whole, Sirt1's regulation of mitochondrial biogenesis and mitophagy could thus act in concert for mitochondria quality maintenance. The large regulatory repertoire of Sirt1 could potentially be exploited for therapeutics, but a better understanding of the molecular factors it influences and their dynamic interactions would be necessary.

![A schematic diagram illustrating a role for Sirt1 in both mitochondrial biogenesis and mitophagy. Caloric restriction (CR) and energetic status that elevates Sirt1 levels or NAD^+^ levels could promote accumulation of PGC-1α in the nucleus, which results in the transcription of genes that are necessary for mitochondrial function and biogenesis. How Sirt1 could promote mitophagy is less clear. However, nicotinamide, which increases NAD^+^ levels and Sirt1 activity, could trigger mitophagy. Sirt1's regulation of mitochondrial biogenesis and mitophagy could function in concert for mitochondria quality maintenance.](molce-39-2-87f1){#f1-molce-39-2-87}
